ArticlePlastic and reconstructive surgery. Global open2024
A Retrospective Analysis of Safety in Participants Treated with a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Filler.
Article in Plastic and reconstructive surgery. Global open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Global Recommendations for Facial Rejuvenation Using a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable.Journal of cosmetic dermatology · 2026Guideline
- Combined and Hybrid Treatments of Hyaluronic Acid (HA) and Calcium Hydroxylapatite (CaHA): A Systematic Review of Mechanisms of Action, Aesthetic Effectiveness, Satisfaction, and Safety Profile.Aesthetic plastic surgery · 2025Pooled it
- Preliminary Investigation and Safety Profile of a Novel Hybrid Filler (Hyaluronic Acid-Calcium Hydroxylapatite) in Asian Facial Rejuvenation.Plastic and reconstructive surgery. Global open · 2026Article
- Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations.Aesthetic surgery journal. Open forum · 2026Article
- Expert Panel Guidelines for Hybrid CaHA-CMC/CPM-HA Fillers in the Mexican Population.Journal of cosmetic dermatology · 2025Article
- A Prospective, Open-Label, Post Marketing Study of the Safety and Effectiveness of a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable.Journal of cosmetic dermatology · 2025Article
- Feasibility of calcium hydroxyapatite (Radiesse®) for improving the biomechanical properties of facial burn scars: A pilot study.JPRAS open · 2025Article
- Three Calcium Hydroxylapatite-Based Dermal Fillers Marketed in Mexico: Comparison of Particle Size and Shape Using Electron Microscopy.Journal of cosmetic dermatology · 2025Article
- Modulating rheology and bioactivity in dermal fillers: the emerging role of platelet-rich plasma (PRP).Frontiers in medicine · 2025Review
- Combined Use of HArmonyCa and Hyaluronic Acid Fillers: A Holistic Approach to Facial Rejuvenation.Plastic and reconstructive surgery. Global open · 2024Article
- HArmonyCa™ hybrid filler to restore connective tissue: An Italian real-life retrospective study.Journal of cosmetic dermatology · 2024Article
- Evaluating the Properties of a Dual-Effect Facial Injectable: From Preclinical Data to Real-World Evidence.Clinical, cosmetic and investigational dermatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limited long-term safety data are published on HA/CaHA/L, a hybrid dermal filler combining hyaluronic acid (HA), calcium hydroxyapatite (CaHA), and lidocaine (L). Methods: This retrospective multicenter study assessed treatment-emergent adverse events (TEAEs) in adults treated with HA/CaHA/L. The full analysis set (FAS) included eligible consented adults ( Results: Participants were majority female (94.0%), with Fitzpatrick skin phototypes II/III (80.1%) and a mean age of 50.1 years. Most participants (86.4%) received one HA/CaHA/L treatment. The median time between participants' first HA/CaHA/L treatment and chart review was 15.4 months. Participants received a mean of 2.2 mL (0.5-8.9 mL) filler per treatment. Treated areas were predominantly malar (71.2%) and mandible (69.7%) regions. Most participants (95.0%) had one or more aesthetic treatments other than HA/CaHA/L [eg, other dermal fillers (84.1%), botulinum toxin (63.3%)]. Nineteen (4.7%) FAS participants had 20 documented TEAEs; most (3.5%, Conclusion: The data from this noninterventional retrospective study support the favorable longer term (>12 month) safety profile of HA/CaHA/L.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.